Accuray (NASDAQ:ARAY) Posts Earnings Results, Meets Estimates

Accuray (NASDAQ:ARAY) released its earnings results on Wednesday. The medical equipment provider reported ($0.04) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.04), Zacks reports. Accuray had a negative net margin of 3.48% and a negative return on equity of 33.65%. The firm had revenue of $101.55 million for the quarter, compared to analyst estimates of $98.10 million. During the same period in the prior year, the firm earned ($0.03) earnings per share. Accuray updated its FY 2025 guidance to EPS.

Accuray Stock Up 3.0 %

Shares of NASDAQ:ARAY traded up $0.06 during trading hours on Thursday, reaching $2.09. The stock had a trading volume of 1,645,853 shares, compared to its average volume of 483,350. The stock has a market capitalization of $209.56 million, a price-to-earnings ratio of -13.06 and a beta of 1.40. The firm’s 50 day moving average is $1.89 and its 200-day moving average is $1.84. Accuray has a 1 year low of $1.40 and a 1 year high of $3.05. The company has a debt-to-equity ratio of 3.65, a quick ratio of 0.95 and a current ratio of 1.66.

About Accuray

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.